Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 739

1.

Hypokalaemic quadriparesis following torsemide and spironolactone use.

Kaur U, Chakrabarti SS, Choudhury AK, Gambhir IS.

Natl Med J India. 2018 Nov-Dec;31(6):347-348. doi: 10.4103/0970-258X.262913.

2.

Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction.

Selvaraj S, Claggett B, Shah SJ, Anand I, Rouleau JL, O'Meara E, Desai AS, Lewis EF, Pitt B, Sweitzer NK, Fang JC, Pfeffer MA, Solomon SD.

Circ Heart Fail. 2018 Nov;11(11):e005288. doi: 10.1161/CIRCHEARTFAILURE.118.005288.

PMID:
30571191
3.

Lack of evidence for feminization of males exposed to spironolactone in utero: A systematic review.

Liszewski W, Boull C.

J Am Acad Dermatol. 2019 Apr;80(4):1147-1148. doi: 10.1016/j.jaad.2018.10.023. Epub 2018 Oct 21. No abstract available.

PMID:
30352280
4.

Antihypertensive effect of the mineralocorticoid receptor antagonist eplerenone: a pooled analysis of patient-level data from comparative trials using regulatory-approved doses.

Fernet M, Beckerman B, Abreu P, Lins K, Vincent J, Burgess E.

Vasc Health Risk Manag. 2018 Sep 20;14:233-246. doi: 10.2147/VHRM.S170141. eCollection 2018.

5.

A unique case of buffalo hump after prolonged use of spironolactone.

Hudd TR, Chugh P, Zaiken K.

J Am Pharm Assoc (2003). 2018 Nov - Dec;58(6):679-681. doi: 10.1016/j.japh.2018.07.005. Epub 2018 Sep 12. No abstract available.

PMID:
30219491
6.

A comparison of the effects of selective and non-selective mineralocorticoid antagonism on glucose homeostasis of heart failure patients with glucose intolerance or type II diabetes: A randomized controlled double-blind trial.

Korol S, White M, O'Meara E, Tournoux F, Racine N, Ducharme A, Rouleau JL, Liszkowski M, Mansour A, Jutras M, Guertin MC, Bernier M, Lavoie J, Leclair G, Neagoe PE, Chaar D, Sirois MG, de Denus S.

Am Heart J. 2018 Oct;204:190-195. doi: 10.1016/j.ahj.2018.07.002. Epub 2018 Jul 10.

PMID:
30097164
7.

Drug reaction with eosinophilia and systemic symptoms caused by spironolactone: Case report.

Fernandes RA, Regateiro FS, Faria E, Martinho A, Gonçalo M, Todo-Bom A.

Contact Dermatitis. 2018 Oct;79(4):255-256. doi: 10.1111/cod.13073. Epub 2018 Jul 16. No abstract available.

PMID:
30009386
8.

Association Between High-Dose Spironolactone and Decongestion in Patients with Acute Heart Failure: An Observational Retrospective Study.

Kapelios CJ, Bonou M, Vogiatzi P, Tzanis G, Mantzouratou P, Lund LH, Barbetseas J.

Am J Cardiovasc Drugs. 2018 Oct;18(5):415-422. doi: 10.1007/s40256-018-0290-3.

PMID:
29971596
9.

Synthesis, bioactivity and mode of action of 5A 5B 6C tricyclic spirolactones as novel antiviral lead compounds.

Zhu YJ, Wu QF, Fan ZJ, Huo JQ, Zhang JL, Zhao B, Lai C, Qian XL, Ma DJ, Wang DW.

Pest Manag Sci. 2019 Jan;75(1):292-301. doi: 10.1002/ps.5115. Epub 2018 Sep 4.

PMID:
29885056
10.

Mineralocorticoid Receptor Blockers and Aldosterone to Renin Ratio: A Randomized Controlled Trial and Observational Data.

Pilz S, Trummer C, Verheyen N, Schwetz V, Pandis M, Aberer F, Grübler MR, Meinitzer A, Bachmann A, Voelkl J, Alesutan I, Catena C, Sechi LA, März W, Obermayer-Pietsch B, Tomaschitz A.

Horm Metab Res. 2018 May;50(5):375-382. doi: 10.1055/a-0604-3249. Epub 2018 May 3.

PMID:
29723896
11.

Individual participant data analysis of two trials on aldosterone blockade in myocardial infarction.

Beygui F, Van Belle E, Ecollan P, Machecourt J, Hamm CW, Lopez De Sa E, Flather M, Verheugt FWA, Vicaut E, Zannad F, Pitt B, Montalescot G.

Heart. 2018 Nov;104(22):1843-1849. doi: 10.1136/heartjnl-2018-312950. Epub 2018 Apr 25.

PMID:
29695512
12.

Spironolactone is superior to hydrochlorothiazide for blood pressure control and arterial stiffness improvement: A prospective study.

Liu Y, Dai S, Liu L, Liao H, Xiao C.

Medicine (Baltimore). 2018 Apr;97(16):e0500. doi: 10.1097/MD.0000000000010500.

13.

Treatment of Unruptured Cerebral Aneurysms with the Mineralocorticoid Receptor Blocker Eplerenone-Pilot Study.

Nagahiro S, Tada Y, Satomi J, Kinouchi T, Kuwayama K, Yagi K, Nakajima K, Matsushita N, Miyamoto T, Yamaguchi T, Shimada K, Korai M, Mure H, Okayama Y, Abe T, Harada M, Kitazato KT, Kanematsu Y.

J Stroke Cerebrovasc Dis. 2018 Aug;27(8):2134-2140. doi: 10.1016/j.jstrokecerebrovasdis.2018.03.008. Epub 2018 Apr 2.

14.

Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial.

Desai AS, Liu J, Pfeffer MA, Claggett B, Fleg J, Lewis EF, McKinlay S, O'Meara E, Shah SJ, Sweitzer NK, Solomon S, Pitt B.

J Card Fail. 2018 May;24(5):313-320. doi: 10.1016/j.cardfail.2018.03.002. Epub 2018 Mar 20.

PMID:
29572190
15.

Spironolactone Versus Clonidine as a Fourth-Drug Therapy for Resistant Hypertension: The ReHOT Randomized Study (Resistant Hypertension Optimal Treatment).

Krieger EM, Drager LF, Giorgi DMA, Pereira AC, Barreto-Filho JAS, Nogueira AR, Mill JG, Lotufo PA, Amodeo C, Batista MC, Bodanese LC, Carvalho ACC, Castro I, Chaves H, Costa EAS, Feitosa GS, Franco RJS, Fuchs FD, Guimarães AC, Jardim PC, Machado CA, Magalhães ME, Mion D Jr, Nascimento RM, Nobre F, Nóbrega AC, Ribeiro ALP, Rodrigues-Sobrinho CR, Sanjuliani AF, Teixeira MDCB, Krieger JE; ReHOT Investigators.

Hypertension. 2018 Apr;71(4):681-690. doi: 10.1161/HYPERTENSIONAHA.117.10662. Epub 2018 Feb 20.

PMID:
29463627
16.

Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease.

Pitt B, Bushinsky DA, Kitzman DW, Ruschitzka F, Metra M, Filippatos G, Rossignol P, Du Mond C, Garza D, Berman L, Lainscak M; Patiromer-204 Investigators.

ESC Heart Fail. 2018 Jun;5(3):257-266. doi: 10.1002/ehf2.12265. Epub 2018 Jan 25.

17.

The SEISICAT study: a pilot study assessing efficacy and safety of spironolactone in cats with congestive heart failure secondary to cardiomyopathy.

James R, Guillot E, Garelli-Paar C, Huxley J, Grassi V, Cobb M.

J Vet Cardiol. 2018 Feb;20(1):1-12. doi: 10.1016/j.jvc.2017.11.001. Epub 2017 Dec 23.

PMID:
29277469
18.

Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone.

Sinclair RD.

Int J Dermatol. 2018 Jan;57(1):104-109. doi: 10.1111/ijd.13838. Epub 2017 Dec 12.

PMID:
29231239
19.

Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction.

Rossignol P, Claggett BL, Liu J, Vardeny O, Pitt B, Zannad F, Solomon S.

Am J Hypertens. 2018 Mar 10;31(4):407-414. doi: 10.1093/ajh/hpx210.

20.

Biochemical monitoring after initiation of aldosterone antagonist therapy in users of renin-angiotensin system blockers: a UK primary care cohort study.

Sinnott SJ, Mansfield KE, Schmidt M, Bhaskaran K, Smeeth L, Nitsch D, Tomlinson LA.

BMJ Open. 2017 Nov 16;7(11):e018153. doi: 10.1136/bmjopen-2017-018153.

Supplemental Content

Loading ...
Support Center